Nicolas de Prost, Etienne Audureau, Antoine Guillon, Lynda Handala, Sebastien Preau, Aurelie Guigon, Fabrice Uhel, Quentin Le Hingrat, Flora Delamaire, Claire Grolhier, Fabienne Tamion, Alice Moisan, Cedric Darreau, Jean Thomin, Damien Contou, Amandine Henry, Thomas Daix, Sebastien Hantz, Clement Saccheri, Valerie Giordanengo, Tai Pham, Amal Chaghouri, Pierre Bay, JeanMichel Pawlotsky, Slim Fourati
{"title":"COVID-19 重症患者中与 SARS-CoV-2 Omicron 变体 JN.1 相关的临床表型和预后：一项前瞻性多中心队列研究","authors":"Nicolas de Prost, Etienne Audureau, Antoine Guillon, Lynda Handala, Sebastien Preau, Aurelie Guigon, Fabrice Uhel, Quentin Le Hingrat, Flora Delamaire, Claire Grolhier, Fabienne Tamion, Alice Moisan, Cedric Darreau, Jean Thomin, Damien Contou, Amandine Henry, Thomas Daix, Sebastien Hantz, Clement Saccheri, Valerie Giordanengo, Tai Pham, Amal Chaghouri, Pierre Bay, JeanMichel Pawlotsky, Slim Fourati","doi":"10.1101/2024.03.11.24304075","DOIUrl":null,"url":null,"abstract":"A notable increase in severe cases of COVID-19, with significant hospitalizations due to the emergence and spread of JN.1 was observed worldwide in late 2023 and early 2024. During the study period (November 2022-January 2024), 56 JN.1- and 126 XBB-infected patients were prospectively enrolled in 40 French intensive care units. JN.1-infected patients were more likely to be obese (35.7% vs 20.8%; p=0.033) and less frequently immunosuppressed than others (20.4% vs 41.4%; p=0.010). JN.1-infected patients required invasive mechanical ventilation support in 29.1%, 87.5% of them received dexamethasone, 14.5% tocilizumab and none received monoclonal antibodies. Day-28 mortality of JN.1-infected patients was 14.6%.","PeriodicalId":501249,"journal":{"name":"medRxiv - Intensive Care and Critical Care Medicine","volume":"113 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron variant JN.1 in critically ill COVID-19 patients: a prospective, multicenter cohort study\",\"authors\":\"Nicolas de Prost, Etienne Audureau, Antoine Guillon, Lynda Handala, Sebastien Preau, Aurelie Guigon, Fabrice Uhel, Quentin Le Hingrat, Flora Delamaire, Claire Grolhier, Fabienne Tamion, Alice Moisan, Cedric Darreau, Jean Thomin, Damien Contou, Amandine Henry, Thomas Daix, Sebastien Hantz, Clement Saccheri, Valerie Giordanengo, Tai Pham, Amal Chaghouri, Pierre Bay, JeanMichel Pawlotsky, Slim Fourati\",\"doi\":\"10.1101/2024.03.11.24304075\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A notable increase in severe cases of COVID-19, with significant hospitalizations due to the emergence and spread of JN.1 was observed worldwide in late 2023 and early 2024. During the study period (November 2022-January 2024), 56 JN.1- and 126 XBB-infected patients were prospectively enrolled in 40 French intensive care units. JN.1-infected patients were more likely to be obese (35.7% vs 20.8%; p=0.033) and less frequently immunosuppressed than others (20.4% vs 41.4%; p=0.010). JN.1-infected patients required invasive mechanical ventilation support in 29.1%, 87.5% of them received dexamethasone, 14.5% tocilizumab and none received monoclonal antibodies. Day-28 mortality of JN.1-infected patients was 14.6%.\",\"PeriodicalId\":501249,\"journal\":{\"name\":\"medRxiv - Intensive Care and Critical Care Medicine\",\"volume\":\"113 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"medRxiv - Intensive Care and Critical Care Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2024.03.11.24304075\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Intensive Care and Critical Care Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.03.11.24304075","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron variant JN.1 in critically ill COVID-19 patients: a prospective, multicenter cohort study
A notable increase in severe cases of COVID-19, with significant hospitalizations due to the emergence and spread of JN.1 was observed worldwide in late 2023 and early 2024. During the study period (November 2022-January 2024), 56 JN.1- and 126 XBB-infected patients were prospectively enrolled in 40 French intensive care units. JN.1-infected patients were more likely to be obese (35.7% vs 20.8%; p=0.033) and less frequently immunosuppressed than others (20.4% vs 41.4%; p=0.010). JN.1-infected patients required invasive mechanical ventilation support in 29.1%, 87.5% of them received dexamethasone, 14.5% tocilizumab and none received monoclonal antibodies. Day-28 mortality of JN.1-infected patients was 14.6%.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
